GPX4 and pancreatic neoplasm: Both rapamycin (classical autophagy inducer) and RSL3 can block mechanistic target of rapamycin kinase (MTOR) activation and cause GPX4 protein degradation in human pancreatic cancer cells, which can restore or enhance the anticancer activity of gemcitabine in vitro or in xenogeneic PDAC models (Liu Y. et al., 2021b).